The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of these two cytokines on T cells, natural killer cells, and antigen-presenting cells.

Later this month, the US Food and Drug Administration (FDA) will decide whether a new psoriasis drug, Stelara (ustekinumab), can enter the market. The human monoclonal antibody (mAb), developed by ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

Medscape Dermatology, October 02, 2024 FDA Approves Ustekinumab Biosimilar Otulfi ... weight to overweight had a higher risk for atopic dermatitis, while those who lost weight appeared to reduce ...

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...